Sequenom Buys SensiGen

San Diego-based Sequenom, a developer of genetic analysis products, said Monday afternoon that it has acquired SensiGen LLC, a biotechnology firm based in Ann Arbor, Michigan. Sequenom said it paid $8.7M for SensiGen, including earn-out milestone payments. SenSiGen develops gene-based molecular tests, to detect and monitor human papillomavirus (HPV), systemic lupus erythematosus (Lupus), chronic kidney disease (CKD), inflammatory bowel disease (IBD), and other conditions. Sequenom said it acquired all of SensiGen's currently developed assays in a combination of stock and cash.